Answers are grounded in this paper and cite their sources.
Biliary tract cancers (BTCs) are uncommon malignancies with poor outcomes, with many patients presenting with advanced, unresectable disease. Since publication of our 2023 practical guide, substantial advances have changed the systemic treatment landscape for BTC in Canada. Updated results from the TOPAZ-1 and KEYNOTE-966 trials have reinforced gemcitabine-cisplatin (GemCis) plus immunotherapy as the standard first-line treatment for unresectable or advanced BTC. Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) remains the standard second-line therapy for genetically unselected disease, while emerging evidence highlights additional approaches that may benefit selected patients. Comprehensive biomarker testing is increasingly important, with targeted therapies available through public reimbursement, clinical trials, or special access programs for patients with FGFR2 fusions or rearrangements, HER2 overexpression, IDH1 mutations, NTRK fusions, microsatellite instability/mismatch repair deficiency, and other actionable genomic alterations. Neoadjuvant therapy is an evolving approach for selected patients with resectable disease, with recent studies providing encouraging results, while adjuvant capecitabine remains the standard following curative-intent resection. Locoregional therapies, remain options for carefully selected patients, particularly those with liver-dominant disease. Despite these advances, access to therapies remains an important consideration in Canada, and multidisciplinary care and clinical trial participation remain essential to optimize outcomes.
No takes yet. Share an insight, caveat, or question.
Ramjeesingh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: